Oral session:
- Positive Impact of CT1812 Treatment on Plasma Biomarkers in Lower p-tau217 Subgroup Aligns with Clinical Benefits in Mild-to-Moderate AD Patients
01 April 2025 at 2:45pm CET
Mary Hamby, Ph.D., VP of Research, Cognition Therapeutics
Posters:
- CSF Proteomic Biomarker Analysis from Phase 2 Study Shine Identified Effects of S2R Modulator CT1812 in Alzheimer’s Disease
- Identification of CSF Proteins That Correlate with Cognitive Outcomes in Participants of Phase 2 Study Shine Evaluating Effects of CT1812 in Patients with Alzheimer’s Disease
- Identification of Molecular Correlates with CT1812 Treatment-related Decrease in NfL CSF Levels Connected to Sigma-2 Receptor